APA 6th Edition Čalkić, L., Bajramović-Omeragić, L., Husić-Selimović, A. & Aličković, I. (2017). HBsAg-SEROKONVERZIJA U LIJEČENJU KRONIČNOG HEPATITISA B PEGILIRANIM INTERFERONOM. Liječnički vjesnik, 139 (1-2), 0-0. Retrieved from https://hrcak.srce.hr/178444
MLA 8th Edition Čalkić, Lejla, et al. "HBsAg-SEROKONVERZIJA U LIJEČENJU KRONIČNOG HEPATITISA B PEGILIRANIM INTERFERONOM." Liječnički vjesnik, vol. 139, no. 1-2, 2017, pp. 0-0. https://hrcak.srce.hr/178444. Accessed 28 Feb. 2020.
Chicago 17th Edition Čalkić, Lejla, Lejla Bajramović-Omeragić, Azra Husić-Selimović and Ibrahim Aličković. "HBsAg-SEROKONVERZIJA U LIJEČENJU KRONIČNOG HEPATITISA B PEGILIRANIM INTERFERONOM." Liječnički vjesnik 139, no. 1-2 (2017): 0-0. https://hrcak.srce.hr/178444
Harvard Čalkić, L., et al. (2017). 'HBsAg-SEROKONVERZIJA U LIJEČENJU KRONIČNOG HEPATITISA B PEGILIRANIM INTERFERONOM', Liječnički vjesnik, 139(1-2), pp. 0-0. Available at: https://hrcak.srce.hr/178444 (Accessed 28 February 2020)
Vancouver Čalkić L, Bajramović-Omeragić L, Husić-Selimović A, Aličković I. HBsAg-SEROKONVERZIJA U LIJEČENJU KRONIČNOG HEPATITISA B PEGILIRANIM INTERFERONOM. Liječnički vjesnik [Internet]. 2017 [cited 2020 February 28];139(1-2):0-0. Available from: https://hrcak.srce.hr/178444
IEEE L. Čalkić, L. Bajramović-Omeragić, A. Husić-Selimović and I. Aličković, "HBsAg-SEROKONVERZIJA U LIJEČENJU KRONIČNOG HEPATITISA B PEGILIRANIM INTERFERONOM", Liječnički vjesnik, vol.139, no. 1-2, pp. 0-0, 2017. [Online]. Available: https://hrcak.srce.hr/178444. [Accessed: 28 February 2020]
Abstracts The ideal goal of antiviral therapy or cure of chronic hepatitis B is HBsAg clearance and HBsAg seroconversion.
According to modern guidelines of all Associations for liver diseases pegylated interferon alfa-2a and nucleos(t)ide
analogues (entecavir, tenofovir) are fi rst choice in the treatment of chronic hepatitis B. The aim of the study was to evaluate
the success of the treatment of patients with chronic hepatitis B who received pegylated interferon. At the end of ten year
period, HBV DNA <50 IU/ml and HBsAg seroconversion achieved 4 (4/55, 7.00%) patients. All were HBeAg negative.
Additionally, is presented the case of patients, who, after the treatment, had the shortest period of healing. Patient is a man,
aged 47 years, with the newly discovered HBeAg negative chronic hepatitis B and pronounced activity of serum aminotransferases.
He was treated with pegylated interferon alfa-2a, 180 μg once a week, for 48 weeks. After antiviral therapy,
the patient is HBV DNA negative, HBsAg negative and neat aminotransferases, and 12 months after completion of antiviral
therapy comes to HBsAg seroconversion. The degree of cure of chronic hepatitis B, unfortunately, has not been entirely
satisfactory, with the exception of the few individual cases